EHA 2018 | First-in-human CLL1-CD33 compound CAR T-cells for AML
Dr Fang Liu, of Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China, discusses first-in-human CLL1-CD33 compound CAR T-cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia (AML). This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.
Get great new content delivered to your inboxSign up